SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is driving significant conversation as escalating US-EU trade tensions, particularly over Greenland and proposed tariffs, spark widespread market uncertainty and a risk-off shift. The community is sharply divided, with intense debate over whether current volatility signals a deeper correction or presents a key buying opportunity amidst ongoing institutional interest and broader macroeconomic shifts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is experiencing significant volatility amid escalating geopolitical tensions, notably the US asserting control over Venezuela's oil and ongoing debates surrounding US tariffs, fueling a "flight to quality" narrative for some. The community is actively discussing whether these events, alongside large institutional bond purchases, will continue to boost Treasuries as a safe haven or intensify concerns over US debt and the Federal Reserve's independence.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices sharply reverse, primarily driven by dramatically warmer weather forecasts that are erasing previous cold-snap gains. The community is actively discussing the extreme volatility and "widow maker" nature of natural gas ETFs, with many attempting to capitalize on KOLD's rapid ascent amidst widespread price uncertainty. This significant shift in winter weather expectations is compelling traders to adjust positions, leading to rapid price movements in inverse natural gas products.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.<stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.<h2 class="st-heading-2">Upcoming Clinical Milestones</h2>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;TGTX stock has declined by over 6% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

Equity

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.


<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

<ul class="summary-bullets"><li>Tempus’ 2025 Total Contract Value (TCV) exceeded $1.1 billion.</li><li>The 2025 agreement roster includes global pharma companies such as AstraZeneca, GlaxoSmithKline, and Pfizer.</li><li>Revenue from data and software-based offerings is expected to be approximately $316 million for 2025.</li></ul>Tempus AI, Inc. (TEM) stock gained over 11% in Monday’s premarket after the company reported that its Total Contract Value (TCV) surpassed $1.1 billion by the end of December 2025.Tempus uses artificial intelligence to work with large and diverse sets of medical data and provides tools that help doctors make more personalized treatment decisions.<h2 class="st-heading-2">Record Contract Growth</h2>Tempus secured data and analytics agreements with more than 70 organizations in the last year, showing the broad adoption of its multimodal data platform.&nbsp;The 2025 agreement roster spans global pharmas such as AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, and Merck alongside biotech partners like Incyte and Whitehawk Therapeutics.&nbsp;<blockquote>“Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”-Jim Rogers, CFO, Tempus</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/TEM">Tempus AI stock</a> moved to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Retention And Revenue Strength</h2>Tempus also reported strong client retention, with net revenue retention around 126% as existing users increased their commitments in 2025.&nbsp;The company also released its outlook for both the fourth quarter (Q4) and the full year of 2025. For the year ending Dec. 31, 2025, Tempus expects total revenue to reach roughly $1.27 billion, a whopping 83% year-over-year increase. The company sees diagnostic testing as the primary growth engine, generating about $955 million in annual revenue.&nbsp;Revenue from data and software-based offerings is expected to be approximately $316 million for the year. For Q4, Tempus expects revenue to climb to nearly $367 million.&nbsp;TEM stock has gained over 104% in the last 12 months.&nbsp;Also See:<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-as-amazon-turns-up-heat-on-weight-loss-drugs/cmU9u36R43M"> Why Is HIMS Stock Slipping Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen.

Why Is Tempus AI Stock Surging 11% Premarket Today? 

Tempus secured data and analytics agreements with more than 70 organizations in 2025, showing the broad adoption of its multimodal data platform. 

<ul class="summary-bullets"><li>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026.</li><li>The company’s total revenue for fiscal 2025 is projected around $370.2 million to $370.4 million.</li><li>Looking ahead, the company has set a revenue forecast for fiscal 2026 between $365 million and $375 million.</li></ul>InMode (INMD) stock is gaining investor attention in Friday’s premarket after the medical technology provider announced its fourth quarter (Q4) sales outlook.The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data.&nbsp;<h2 class="st-heading-2">2025 And 2026 Outlook&nbsp;</h2>The firm is scheduled to report its financial performance for Q4 and fiscal 2025 ahead of the market open on Tuesday, Feb. 10, 2026. The company’s total revenue for fiscal 2025 is projected to be around $370.2 million to $370.4 million, below the analysts' consensus estimate of $371 million, as per FiscalAI data.InMode expects a non-GAAP gross margin near the high end of the 70% range for the full 2025 fiscal year.&nbsp;Looking ahead, the company has set a revenue forecast for fiscal 2026 between approximately $365 million and $375 million.&nbsp;<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> inched 0.8% higher in Friday’s premarket.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory while message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_09_055125_png_79a97af5f3.webp" alt="INMD’s Sentiment Meter and Message Volume as of 05:45 a.m. ET on Jan. 9, 2026 | Source: Stocktwits" width="926" height="105"></figure>A bullish Stocktwits user highlighted sequential growth and high margins.&nbsp;<stembedurl>https://stocktwits.com/thinkandpick/message/641307067</stembedurl>Another user pointed to ongoing pressure in the aesthetic device sector, noting that demand remains subdued, but added that the latest outlook broadly aligns with the company’s earlier outlook for 2025, suggesting performance is tracking as expected.<stembedurl>https://stocktwits.com/findingthestock/message/641285697</stembedurl><h2 class="st-heading-2">Brokerage Radar&nbsp;</h2>In December, Canaccord cut its price target on InMode to $15 from $16 and kept a ‘Hold’ rating on the stock, according to TheFly. The firm said it still has a positive long-term view on the medical technology industry going into 2026, noting that mid-sized company valuations remain low, and deal activity is increasing.INMD stock has declined by over 10% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-big-oil-invest-at-least-100-billion-venezuela/cmU29w3R4d2">Trump Says Big Oil Will Invest At Least $100 Billion To Rebuild Venezuela's Oil Infrastructure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

INMD Stock Draws Investor Attention On Q4 Financial Update

The company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, compared with the analyst consensus estimate of $104.64 million, according to FiscalAI data. 

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

UBS says this sector remains a high-quality, defensive investment theme

Investing.com -- UBS continues to view the medical devices sector as a high-quality, defensive investment theme, supported by long-term demographic shifts and rising global demand.

Sector ETFs Likely to Gain on May Inflation Data

Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick

Investing.com -- Citi analysts revised their MedTech coverage following a volatile first quarter, with several rating changes and adjustments to target prices.

IHI
iShares US Medical Devices ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHI News

IHIiShares US Medical Devices ETF